Tucatinib Plus Trastuzumab Emtansine May Benefit Patients With Advanced or Metastatic HER2-Positive Breast Cancer
December 08, 2023
December 08, 2023
SAN ANTONIO, Texas, Dec. 8 (TNSres) -- The American Association for Cancer Research posted the following news release:
A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial presented at the San Antonio Breast Cancer Symposium, held . . .
A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial presented at the San Antonio Breast Cancer Symposium, held . . .